Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Shirish Gadgeel"'
Autor:
Michael Boyer, Rina Hui, Damien Urban, Philip Clingan, Wu-Chou Su, Celine Devaux, Shirish Gadgeel, Marina Garassino, Lance Leopold, Jeannie Daniel, Mihaela C. Munteanu, Ayman Samkari, Yiwen Luo, Delvys Rodriguez Abreu
Publikováno v:
BMC Cancer, Vol 23, Iss S1, Pp 1-12 (2024)
Abstract Background The combination of the checkpoint inhibitor (CPI) pembrolizumab and platinum-based chemotherapy is effective frontline therapy for advanced non-small cell lung cancer (NSCLC) lacking targetable mutations. Indoleamine 2,3- dioxygen
Externí odkaz:
https://doaj.org/article/f859d06395444ff68173b8d586898c31
Autor:
Sondos Al Khatib, MD, Khalid Adil, MD, Lonni Schultz, MS, Shirish Gadgeel, MD, Andrew Popoff, MD, Munther Ajlouni, MD, Michael Simoff, MD, Benjamin Movsas, MD, Aharon Feldman, MD
Publikováno v:
Advances in Radiation Oncology, Vol 8, Iss 4, Pp 101190- (2023)
Purpose: As screening chest computed tomography for patients at high risk for cancer has become more widely accepted, increasing numbers of patients with early-stage small cell lung cancer (SCLC) are being diagnosed. Although surgery is an accepted o
Externí odkaz:
https://doaj.org/article/21da2b05a5884c12831f5f6934a28ce6
Autor:
Fawzi Abu Rous, MD, Pin Li, PhD, Shannon Carskadon, MS, Sunny RK. Singh, MD, Rebecca Chacko, MD, Hassan Abushukair, BS, Shirish Gadgeel, MD, Nallasivam Palanisamy, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100486- (2023)
Introduction: Amplification of 3q is the most common genetic alteration identified in squamous cell carcinoma of the lung (LUSC), with the most frequent amplified region being 3q26 to 3q28. Methods: In this analysis, we aim to describe the prognostic
Externí odkaz:
https://doaj.org/article/c7df366176e24c1d96b5f847e1251dcf
Autor:
Marina C. Garassino, MD, Shirish Gadgeel, MD, Silvia Novello, MD, PhD, Balazs Halmos, MD, Enriqueta Felip, MD, Giovanna Speranza, MD, Rina Hui, PhD, Edward B. Garon, MD, Hidehito Horinouchi, MD, PhD, Shunichi Sugawara, MD, PhD, Delvys Rodriguez-Abreu, MD, PhD, Martin Reck, MD, Razvan Cristescu, PhD, Deepti Aurora-Garg, PhD, Andrey Loboda, PhD, Jared Lunceford, PhD, Julie Kobie, PhD, Mark Ayers, MS, Bilal Piperdi, MD, M. Catherine Pietanza, MD, Luis Paz-Ares, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 1, Pp 100431- (2023)
Introduction: We evaluated tissue tumor mutational burden (tTMB) and mutations in STK11, KEAP1, and KRAS as biomarkers for outcomes with pembrolizumab plus platinum-based chemotherapy (pembrolizumab-combination) for NSCLC among patients in the phase
Externí odkaz:
https://doaj.org/article/5b31e33aa86a4148993ed9fca9e915ac
Autor:
Shirish Gadgeel, MD, Jhanelle E. Gray, MD, Maria Teresa Rizzo, MD, Patrick Peterson, PhD, Jong Seok Kim, MD, Delvys Rodríguez-Abreu, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100389- (2022)
Introduction: The aim of this study was to evaluate the efficacy of pemetrexed and platinum plus pembrolizumab by baseline tumor burden. Methods: A total of 616 patients in the intention-to-treat population of the KEYNOTE-189 study were included in t
Externí odkaz:
https://doaj.org/article/6fb84dd7ecee4edf94a302b903fdc851
Autor:
Chan Yeu Pu, MD, MS, Christine M. Lusk, MPH, Christine Neslund-Dudas, PhD, Shirish Gadgeel, MD, Ayman O. Soubani, MD, Ann G. Schwartz, MPH, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 8, Pp 100377- (2022)
Introduction: Lung cancer screening criteria should select candidates with minimal cardiopulmonary comorbidities who are fit for curative lung cancer resection. Methods: We retrospectively analyzed 728 patients with lung cancer for screening eligibil
Externí odkaz:
https://doaj.org/article/42cd0e42675d4f489a886ca91d55a748
Autor:
Dong-Wan Kim, MD, PhD, Shirish Gadgeel, MD, Scott N. Gettinger, MD, Gregory J. Riely, MD, PhD, Geoffrey R. Oxnard, MD, Tarek Mekhail, MD, Peter Schmid, MD, PhD, Afshin Dowlati, MD, Rebecca S. Heist, MD, MPH, Antoinette J. Wozniak, MD, Jatinder Singh, PhD, Edward Cha, MD, PhD, Jessica Spahn, PhD, Sai-Hong Ignatius Ou, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 8, Pp 100367- (2022)
Introduction: Alectinib is a preferred first-line treatment option for advanced ALK-positive NSCLC. Combination regimens of alectinib with immune checkpoint inhibitors are being evaluated for synergistic effects. Methods: Adults with treatment-naive,
Externí odkaz:
https://doaj.org/article/ef3f254cb8784bd19307c98d578cc81c
Autor:
Marina C. Garassino, Shirish Gadgeel, Giovanna Speranza, Enriqueta Felip, Emilio Esteban, Manuel Dómine, Maximilian J. Hochmair, Steven F. Powell, Helge G. Bischoff, Nir Peled, Francesco Grossi, Ross R. Jennens, Martin Reck, Rina Hui, Edward B. Garon, Takayasu Kurata, Jhanelle E. Gray, Paul Schwarzenberger, Erin Jensen, M. Catherine Pietanza, Delvys Rodríguez-Abreu
Publikováno v:
Scientia
Pembrolizumab; Non-small-cell lung cancer Pembrolizumab; Cáncer de pulmón de células no pequeñas Pembrolizumab; Càncer de pulmó de cèl·lules no petites Clinical trials frequently include multiple end points that mature at different times. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::374e74c86ca13e92597e504ff2706d68
https://doi.org/10.1200/jco.22.01989
https://doi.org/10.1200/jco.22.01989
Autor:
Julien Mazières, Solange Peters, Andrés Cardona, Martin Reck, David Gandara, Denis Moro-Sibilot, Shirish Gadgeel, Stefanie Morris, Diana Mendus, Marcus Ballinger, Achim Rittmeyer
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background Treatment-induced accelerated tumor growth is a progression pattern reported with immune checkpoint inhibitors that has never been evaluated in randomized phase III studies because it requires two pretreatment scans. This study aimed to de
Externí odkaz:
https://doaj.org/article/083737184a6d4a08bbdbf8e494bd6434
Publikováno v:
Molecular Cancer Therapeutics. 22:381-392
FDA-approved enzalutamide is commonly prescribed to reduce the growth of advanced prostate cancer by blocking androgen receptor function. However, enzalutamide-resistant prostate cancer (ERPC) invariably develops and progresses to metastatic, lethal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33ce5a3645daf567ce7d290671a14784
https://doi.org/10.1158/1535-7163.mct-21-1002
https://doi.org/10.1158/1535-7163.mct-21-1002